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Abstract 
Sarcoidosis is a multisystem granulomatous disorder of unknown etiology that can involve virtually 
all organ systems. Whereas most patients present without symptoms, progressive and disabling 
organ failure can occur in up to 10% of subjects. Somatostatin receptor (SSTR)-directed peptide 
receptor radionuclide therapy (PRRT) has recently received market authorization for treatment of 
SSTR-positive neuroendocrine tumors.  
Methods: We describe the first case series comprising two patients with refractory multi-organ 
involvement of sarcoidosis who received 4 cycles of PRRT.  
Results: PRRT was well-tolerated without any acute adverse effects. No relevant toxicities could 
be recorded during follow-up. Therapy resulted in partial response accompanied by a pronounced 
reduction in pain (patient #1) and stable disease regarding morphology as well as disease activity 
(patient #2), respectively. 
Conclusion: Peptide receptor radionuclide therapy in sarcoidosis is feasible and might be a new 
valuable tool in patients with otherwise treatment-refractory disease. Given the long experience 
with and good tolerability of PRRT, further evaluation of this new treatment option for otherwise 
treatment-refractory sarcoidosis in larger patient cohorts is warranted. 
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Introduction 
Sarcoidosis is a multisystem granulomatous 
disorder of unknown etiology that can virtually 
involve all organ systems (1). Whereas most patients 
present without symptoms, progressive and disabling 
organ failure can occur in up to 10% of subjects. 
Glucocorticoids are the most commonly used 
medication for the treatment of sarcoidosis. 
Alternative therapeutic approaches include the use of 
immunosuppressive, cytotoxic, and antimalarial 
drugs (2, 3). 
Somatostatin receptor (SSTR)-directed peptide 
receptor radionuclide therapy (PRRT) has recently 
received market authorization for treatment of 
SSTR-positive neuroendocrine tumors as 
improvement of progression-free and overall survival 
has been shown (4). We have recently reported on 
encouraging results after a single course of PRRT in a 
46-year-old woman with treatment-refractory 
multi-organ sarcoidosis (5). This patient had been 









courses of uveitis, bihilar lymphadenopathy, multiple 
lung nodules as well as splenomegaly raised concern 
for a systemic immune-mediated disease. Mediastinal 
lymph node biopsy confirmed presence of 
non-caseating granulomas highly consistent with 
sarcoidosis. Initial treatment with high-dose 
prednisone (100 mg/day) was terminated after 3 
months due to persistent inflammatory activity and 
new onset of diabetes. Additionally, the patient 
perceived growing bone pain due to osseous 
involvement. As an alternative, methotrexate (25 
mg/week) and dipyrone were prescribed but had no 
beneficial effect. In the following years, the patient 
experienced increasing pain and etanercept (50 
mg/week) was administered. A combination of 
methotrexate (15 mg/week) and adalimumab (40 
mg/week), cyclophosphamide and azathioprine 
showed no effect on inflammatory activity or relief of 
symptoms. By mid-2014, the patient had exhausted all 
conventional treatment options and still suffered from 
debilitating bone pain. On a compassionate use base, 
PRRT was offered to the patient and resulted in 
significant pain relief as well as partial morphologic 
response. Further treatment cycles were performed in 
analogy to PRRT protocols already established for 
treatment of SSTR-positive tumors.  
The second patient, another 46-year-old woman, 
was referred with chronic progressive sarcoidosis and 
multiple pulmonary and lymph node manifestations. 
After initial diagnosis in 2010, treatment regimens 
including prednisone, methotrexate, cyclophosp-
hamide, and azathioprine failed to achieve disease 
control. At the time point of presentation, she 
complained about pronounced, increasingly painful 
cervical lymphadenopathy. Prednisolone (5 mg/day) 




Standard serum parameters as well as complete 
blood counts were recorded by standard techniques 
prior to and every one to two weeks after each PRRT 
cycle. To determine sarcoidosis activity, serum levels 
of neopterin as well as soluble interleukin receptor 2 
were routinely assessed.  
PET imaging 
For staging and re-staging purposes, positron 
emission tomography/computed tomography (PET/ 
CT) was performed on an integrated scanner (Siemens 
Biograph mCT 64, Siemens, Knoxville, USA) 
consisting out of a Lutetium oxyorthosilicate full-ring 
PET scanner and a 64-slice spiral CT.  
Before acquisition of [18F]FDG-PET, patients 
fasted for at least 6 h. Blood glucose levels were <160 
mg/dL. For SSTR-directed imaging, no fasting was 
required. [68Ga]DOTATOC and [18F]FDG were 
injected intravenously. After a period of 60 min, 
transmission and PET emission data were acquired as 
previously described (6).  
Bone marrow aspiration 
In order to harvest peripheral blood progenitor 
cells as backup in case of severe hematotoxicity, 
mobilization of stem cells by priming with 
granulocyte colony-stimulating factor was attempted 
in patient #1. However, an adequate cell amount 
could not be harvested. Additionally, the patient 
complained about increasing abdominal pain which 
could be allocated to growing splenomegaly thereby 
preventing prolonged or intensified stimulation. 
Instead, bone marrow harvest from the posterior iliac 
crests under general anesthesia was performed and 
yielded a sufficient number of hematopoetic stem 
cells. Due to the favorable toxicity profile without any 
severe hematotoxicity after the first PRRT cycle, no 
additional stem cells for the subsequent cycles or the 
second patient were harvested. 
PRRT 
The clinical ethics committee of our institution 
approved the treatment on a compassionate use base 
(German Drug Act, §13,2b). Both patients gave 
written informed consent prior to therapy. Peptide 
receptor radionuclide therapy was performed 
according to the joint IAEA, EANM and SNMMI 
practical guidance and consisted of a total of four 
individual cycles performed every 12 weeks (7). PRRT 
with 7.7±0.5 GBq of [177Lu]DOTATOC was 
intravenously administered over 30 min. Vital signs 
were documented during the infusion and within 7 
days after administration. The patients were 
followed-up after PRRT including serial blood tests, 
kidney scintigraphy as well as [18F]FDG- and 
SSTR-PET/CT. Severity of therapy-related toxicity 
was recorded according to the National Cancer 
Institute Common Terminology Criteria for Adverse 
Events (CTCAE; version 4.03).  
Post-therapeutic dosimetry 
Post-therapeutic gamma camera whole-body 
imaging was performed at 2 h, 24 h, and 72 h after 
injection of the radiopharmaceutical. At 24 h, 
additional tomographic single photon emission 
computed tomography in combination with low-dose 
computed tomography of the abdomen and pelvis 
(SPECT/CT) was performed (Symbia T2, Siemens 
Healthcare, Erlangen, Germany). Images were 
reconstructed using an iterative ordered-subsets 
expectation maximization algorithm. For selected 





organs and lesions, the count statistics were extracted 
from the planar whole body scans by regions of 
interest techniques and activity time functions were 
deduced by normalization to the activities measured 
by SPECT/CT. After integration over time, these data 
were used to estimate organ absorbed doses. For 
patient #1, activity concentrations in whole blood 
samples taken 5 min, 1 h, 4 h, 1 d, 2 d and 3 d after the 
first administration were measured and the absorbed 
dose to the blood was calculated as a surrogate for the 
dose to the red marrow (8). As dosimetry yielded only 
very low dose values, no blood samples were taken 
after the other therapy courses. 
Results 
In patient #1, SSTR- and [18F]FDG-PET imaging 
demonstrated enhanced tracer accumulation in 
multiple lymph nodes as well as throughout the 
skeleton, consistent with active granulomas. Patient 
#2 presented with highly [68Ga]DOTATOC-avid 
generalized lymphadenopathy. Small pulmonary 
lesions and multiple osseous lesions (as detected by 
[18F]FDG-PET/CT) did not show enhanced SSTR 
expression. Since all (patient #1), respectively most 
(including the clinically most important (cervical) 
lesions) manifestations (patient #2) could be targeted, 
SSTR-directed PRRT was offered on a compassionate 
use base after receiving informed consent. 
Pre-therapeutic assessment of renal function was 
normal in both subjects.  
Toxicity  
Each cycle of PRRT was well tolerated without 
any acute adverse effects. None of the PET/CT and 
SPECT/CT images showed specific activity 
accumulation in the red marrow. No changes in vital 
signs were recorded at any time. In the weeks after 
treatment and during follow-up, no relevant bone 
marrow or other toxicity according to CTCAE 
occurred. Of note, patient #1 experienced only grade 1 
toxicity for hemoglobulin (with a minimum of 10 
g/dL), white blood cells (with a minimum of 3,300 per 
mm3 after the second treatment cycle) and platelets 
(with a minimum of 139,000 per mm3 after the second 
treatment cycle; Table 1). Patient #2 had grade 2 
leukopenia (with decreased white blood cell counts 
prior to PRRT; Table 2). No higher-grade adverse 
events could be recorded. Additionally, no changes in 
kidney function could be observed in both patients, 
emphasizing good tolerability of PRRT. 
 
Table 1. Laboratory data & lung function parameters of patient #1 
 Reference range, adults Prior to 
PRRT 
3 weeks after 
PRRT 






Hemoglobulin (g/dL) 12-16 11.2 10.0 10.7 11.6 12,7 
White-cell count (per mm3) 4,500-11,000 5,800 3,400 3,400 3,300 3,900 
Absolute neutrophil count (ANC, per 
mm3) 
1,200-7,200 4,940 2,768 n/a 2,640 3,276 
Differential count (%)       
Neutrophils 41-70 84.5 81.4 n/a 80 84 
       
Platelet count (per mm3) 150,000-450,000 221,000 221,000 186,000 139,000 152,000 
       
Creatinine (mg/dL) 0.0-0.95 0.79 0.88 0.89 0.79 0.83 
Estimated glomerular filtration rate 
(mL/min 1.73 m2; CKD-EPI) 
 90 79 78 89 84 
       
Soluble interleukin-2 receptor (U/mL) ≤900 1,968 n/a 1,021 n/a 865 
Neopterin (nM) <10 n/a n/a n/a 18.2 11.4 
ACE (U/L) 20-70 57.4 n/a n/a 87.5 46.8 
       
Lung Function       
VC IN 2.49 3.19  2.80   
FVC 3.40 3.16  2.86   
FEV 1 2.93 2.64  2.31   
FEV 1 % FVC  83.47  80.67   
ERV (L) 1.04 0.50  0.53   
       
PEF (L/s) 6.80 6.92  7.23   
MEF 75 (L/s) 5.89 6.72  6.43   
MEF 50 (L/s) 4.15 3.37  2.71   
MEF 25 (L/s) 1.73 1.09  0.82   
       
VC (L) 3.49 3.19  2.87   
FRCpleth (L) 2.83 2.34  2.40   
RV (L) 1.79 1.83  1.87   
TLC (L) 5.36 5.02  4.74   
R tot (kPa·s/L) 0.30 0.29  0.28   
SR tot (kPa·s) 0.96 0.85  0.77   
R eff (kPa·s/L) 0.30 0.23  0.23   
 





Table 2. Laboratory data & lung function parameters of patient #2 
 Reference range, adults Prior to 
PRRT 
3 weeks after 
PRRT 






Hemoglobulin (g/dL) 12-16 12.1 12.2 11.8 12.0 12.1 
White-cell count (per mm3) 4,500-11,000 3,100 2,900 3,500 2,800 3,100 
Absolute neutrophil count (ANC, per 
mm3) 
1,200-7,200 2,092 n/a n/a 1,764 1,760 
Differential count (%)       
Neutrophils 41-70 67.5 n/a n/a 63.0 60.8 
       
Platelet count (per mm3) 150,000-450,000 145,000 n/a 209,000 207,000 186,000 
       
Creatinine( mg/dL) 0.0-0.95 0.69 0.54 0.70 0.70 0.72 
Estimated glomerular filtration rate 
(mL/min 1.73 m2; CKD-EPI) 
 105 n/a 105 104 101 
       
Soluble interleukin-2 receptor (U/mL) ≤900 1,504 1,570 n/a 1,233 1,164 
Neopterin (nM) <10 n/a n/a n/a 17.9 11.9 
ACE (U/L) 20-70 >120 138 n/a 159 119.8 
       
Lung function       
VC IN 2.91 2.68 2.13  2.07 2.45 
FVC 2.85 2.49 2.08  2.14 2.15 
FEV 1 2.44 1.88 1.52  1.53 1.52 
FEV 1 % FVC  75.33 73.03  71.22 70.94 
ERV (L) 1.0 0.16 n/a  0.12 0.25 
       
PEF (L/s) 6.12 3.3 2.91  2.86 2.63 
MEF 75 (L/s) 5.50 2.73 n/a  2.22 2.23 
MEF 50 (L/s) 3.86 1.89 1.32  1.25 1.15 
MEF 25 (L/s) 1.62 0.49 n/a  0.34 0.23 
       
VC (L) 2.91 2.68 2.13  2.31 2.45 
FRCpleth (L) 2.54 1.88 1.42  2.15 1.92 
RV (L) 1.54 1.72 n/a  2.03 1.67 
TLC (L) 4.51 4.41 3.40  4.34 4.12 
R tot (kPa·s/L) 0.30 0.84 n/a  0.72 0.82 
SR tot (kPa·s) 0.96 1.85 n/a  1.85 1.85 
R eff (kPa·s/L) 0.30 0.60 n/a  0.58 0.53 
 
Post-therapeutic dosimetry  
Post-therapeutic scintigraphy with [177Lu] 
DOTATOC was consistent with pre-therapeutic 
[68Ga]DOTATOC-PET/CT imaging. Absorbed lesion 
dose was estimated to reach up to 12 Gy per treatment 
cycle (in patient #1). In patient #2, achieved lesion 
doses were lower than in patient #1 with only 4 Gy 
per treatment cycle. Doses in normal organs were 
acceptable, with 0.64±0.18 Gy/GBq (of administered 
activity) for the kidneys and 0.07±0.02 Gy/GBq for the 
liver–well within the range of values typically 
observed in therapy with 177Lu [7]. The blood 
absorbed dose from the first therapy course in patient 
#1 was 0.016 Gy/GBq indicating a cumulative red 
marrow dose of 0.5 Gy from 4 PRRT cycles. 
Clinical and radiological response 
After achieving a pronounced reduction of pain 
during rest, significantly decreased tracer 
accumulation in all osseous lesions as well as 
mediastinal lymph nodes at first restaging 8 weeks 
after the first treatment cycle, patient #1 demonstrated 
a very good response after completion of all 4 PRRT 
cycles with nearly complete resolution of sarcoidosis 
activity at both [18F]FDG and [68Ga]DOTATOC- 
PET/CT (Figure 1, Supplementary Figure 1). In 
parallel, serum levels of neopterin, ACE and soluble 
interleukin-2 receptor as well as the demand for pain 
relief had significantly dropped (Table 1, 
Supplementary Figure 2). Most importantly, the 
patient reported on sustained well-being after the end 
of therapy. The effects of PRRT were still present 3 
months after end of PRRT without initiation of any 
other treatment and are still ongoing at the time 
present (10 months after completion of PRRT).  
In patient #2, effects of PRRT resulted in a more 
short-lived pain relief. Whereas each treatment cycle 
reduced cervical pain, intensity started to recur 8 
weeks after therapy. At the end of 4 PRRT cycles, 
although a decrease in serum activity parameters 
could be recorded (Table 2), no significant reduction 
in pain could be achieved. In parallel, imaging 
revealed stable disease regarding morphology (with 
non-significant reduction in size) as well as disease 
activity.  







Figure 1: Display of [18F]-FDG-PET/CT and somatostatin receptor-directed PET/CT with [68Ga]-DOTATOC before and 1 year after initiation of peptide receptor 
radionuclide therapy with [177Lu] in patient #1. A total of four cycles have been administered. Both PET projections are displayed with the same intensity. Of note, 
initial bone marrow involvement is more patchy in [68Ga]-DOTATOC-PET/CT as compared to the more diffuse uptake of [18F]-FDG. 
 
 
Figure 2: Display of [18F]-FDG-PET/CT and somatostatin receptor-directed PET/CT with [68Ga]-DOTATOC before and 1 year after initiation of peptide receptor 
radionuclide therapy with [177Lu] in patient #2. After a total of four cycles, stable disease (with a slight reduction in somatostatin receptor expression and increasing 
activity in the spleen) was recorded. Both PET projections are displayed with the same intensity. 
 
Discussion 
Whereas most patients with symptomatic 
sarcoidosis can be successfully treated with 
glucocorticoids, alternative therapies are sometimes 
necessary due to progression of disease or 
non-tolerable side effects of glucocorticoids. Options 
include immunosuppressive therapy (metotrexate, 
azathioprine, leflunomide) or, if no response occurs, 
tumor necrosis factor-alpha (TNF-α) antagonists 
(including infliximab, adalimumab or etanercept) or 
investigational off-label agents such as 
cyclophosphamide. 
Patient #1 suffered from diffuse skeletal 
involvement resulting in debilitating bone pain 
refractory to all conventional therapeutic agents 
including corticosteroids, MTX, azathioprine, 
leflunomide, adalimumab, and cyclophosphamide. 
Treatment options offered were reduced to 
(insufficient) symptomatic pain relief. 
Patient #2 presented with progressive 
pulmonary and ubiquitous lymph node 
manifestations. Treatment regimens including 
prednisone, methotrexate, cyclophosphamide, and 
azathioprine had failed to obtain disease control; at 
the time of presentation, the patient refused TNF-α 
blockage and asked for alternatives.  





Since activated macrophages have been shown 
to overexpress the somatostatin receptor type II on the 
cell surface, which can be visualized by PET/CT 
(9-13), α- or β-radiolabeled SSTR-ligands may be 
beneficial for selectively targeting active sarcoid 
granulomas by means of endoradiotherapy. In both 
cases presented, target expression (SSTR) could be 
proven by [68Ga]DOTATOC-PET/CT. Given the high 
level of suffering and the lack of treatment 
alternatives, PRRT was offered on a compassionate 
use basis. Given the limited experience with PRRT in 
benign inflammatory disorders (in contrast to the long 
experience in NET) and diffuse skeletal involvement 
in patient #1, we opted for stem cell support to be able 
to counteract potential bone marrow depression. 
Therapy with standard activities of 177Lutetium was 
well tolerated and post therapeutic laboratory results 
provided no evidence of major negative effects of 
PRRT on bone marrow or kidney function. Although 
it can be assumed that absorbed doses in the diverse 
granulomas were rather modest, she experienced 
significant subjective benefit from PRRT that could 
also be objectively proven by [18F]FDG- and 
[68Ga]DOTATOC-PET/CT. Of note, the patient is in 
maintained treatment response (without any other 
sarcoidosis-directed therapy) for almost a year after 
end of therapy now, allowing her to resume her 
full-time job as a technician. 
In contrast, though stabilizing disease, PRRT in 
patient #2 achieved only mild and temporary 
improvement of pain levels. Whereas a mild 
reduction in serum sarcoidosis activity parameters 
could be recorded, subjective assessment correlated 
with imaging findings demonstrated no major change 
in disease activity. 6 months after completion of 4 
cycles of PRRT, she decided to start on infliximab, 
which she has been administered three times with 
minor success so far.  
These are the first two cases of therapeutic 
targeting of somatostatin receptors in inflammatory 
diseases. Peptide receptor radionuclide therapy might 
prove a new valuable tool for patients with otherwise 
treatment-refractory sarcoidosis. In a theranostic 
approach, pre-therapeutic SSTR-directed PET/CT can 
serve as read-out to identify eligible patients. Given 
the long experience with and good tolerability of 
PRRT, further evaluation of this new treatment option 
in larger patient cohorts is warranted, opening a novel 
approach to this inflammatory disease. 




ACE: angiotensin-converting enzyme; CTCAE: 
Common Terminology Criteria for Adverse Events; 
ERV: expiratory reserve volume; FEV1: forced 
expiratory volume in 1 second; FRCpleth: functional 
residual capacity; FVC: forced vital capacity; MEF: 
maximal expiratory flow; MTX: methotrexate; PEF: 
peak expiratory flow; PRRT: peptide receptor 
radionuclide therapy; R eff: effective lung resistance; 
R tot: total (airway) resistance; RV: residual volume; 
sR tot: specific total (airway) resistance; SSTR: 
somatostatin receptor; TLC: total lung capacity; 
TNF-α: tumor necrosis factor-alpha; VC IN: 
inspiratory vital capacity; VC: vital capacity. 
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